A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: Randomized, placebo-controlled, double-blind clinical trial

BACKGROUND AND AIMS: Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RA) are widely used for the treatment of type 2 diabetes, and recent studies indicate that they may be cardio- and neuroprotective. The safety and effect of a single dose of exenatide, a short-acting GLP-1RA, on cerebral an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ölmestig, Joakim, Marlet, Ida R., Vilsbøll, Tina, Rungby, Jørgen, Rostrup, Egill, Lambertsen, Kate L., Kruuse, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831269/
https://www.ncbi.nlm.nih.gov/pubmed/36636739
http://dx.doi.org/10.3389/fnagi.2022.899389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831269/
https://www.ncbi.nlm.nih.gov/pubmed/36636739
http://dx.doi.org/10.3389/fnagi.2022.899389

Ejemplares similares